According to information on the MSN Money web site, Adamis Pharmaceuticals has received approval from the U.S. Food & Drug Administration of its Investigational New Drug (IND) application and been give approval to initiate a Phase I/IIa clinical trial of APC-100 for the treatment of men with castration-resistant prostate cancer.
The study will be initiated at the University of Wisconsin Carbone Cancer Center and then extended to Wayne State University Karmanos Cancer Institute. However, there is no information about this trial available yet on the ClinicalTrials.gov web site.
Filed under: Drugs in development Tagged: | APC-100
Search for new and
ongoing trials on the
CTAG PCa web site
